Lung Cancer Clinical Trials in Boston

Showing 361-380 of 553 trials

Efficacy Study of Oral Seliciclib to Treat Non-Small Cell Lung Cancer

NCT00372073

A phase 2 study to evaluate efficacy of oral seliciclib in treating non-small cell lung cancer (NSCLC).

Cyclacel Pharmaceuticals, Inc.187 participantsStarted Aug 2006

Tucson, Arizona, United States • Fountain Valley, California, United States • New Port Richey, Florida, United States +17 more locations

COMPLETEDPhase 1< 1 mile

A Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent Malignancies

NCT00730639

The purpose of this study is to determine the safety and effectiveness of MDX-1106 in patients with certain types of cancer. Another purpose is to determine how MDX-1106 is absorbed and distributed within the body, and how it's eventually eliminated.

Metastatic Castration-resistant Prostrate CancerRenal Cell CarcinomaMetastatic Melanoma+1 more

Bristol-Myers Squibb395 participantsStarted Oct 2008

Scottsdale, Arizona, United States • New Haven, Connecticut, United States • Tampa, Florida, United States +10 more locations

Efficacy Study of Oral Seliciclib to Treat Non-Small Cell Lung Cancer

A Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent Malignancies

Lung Cancer Trials in Other Cities

Pilot Study of a Pharmacy Intervention for Older Adults With Cancer

A Study of MM-121 in Combination With Chemotherapy Versus Chemotherapy Alone in Heregulin Positive NSCLC

Feasibility Study of Enhanced MRI for Early Stage Non Small Cell Lung Cancer (NSCLC)

A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma

A Study of LY3295668 Erbumine in Participants With Extensive-stage Small-Cell Lung Cancer

NeoMend ProGEL™ Pleural Air Leak Sealant Post-Approval Study

Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer

Lung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer

A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU)

Preoperative Chemotherapy and Bevacizumab in Patients With Stage IB (>4 cm), II, or Select Stage III NSCLC

External Control, Observational, Retrospective Study Comparing Pralsetinib to Best Available Therapy in Patients With RET-Fusion Positive NSCLC

Real World Treatment Study of AZD9291 for Advanced/Metastatic EGFR T790M Mutation NSCLC

Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 When Given Together With Chemotherapy and the Effectiveness of This Combination Treatment in Shrinking a Specific Type of Lung Tumors (Small Cell Lung Cancer)

Study to Assess the Effect of Rifampicin on Blood Levels and Safety of AZD9291, in Patients With EGFRm+ NSCLC

Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.

Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors

A Study Comparing MB02 and Avastin® in Subjects With Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

A Comparative Study of BAT1706 and EU Avastin® in Patients With Advanced Non Squamous Non Small Cell Lung Cancer

Other Conditions in Boston